PLIANT THERAPEUTICS INC (PLRX) Stock Fundamental Analysis

NASDAQ:PLRX • US7291391057

1.245 USD
-0.05 (-4.23%)
Last: Feb 20, 2026, 03:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, PLRX scores 1 out of 10 in our fundamental rating. PLRX was compared to 191 industry peers in the Pharmaceuticals industry. PLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PLRX has reported negative net income.
  • In the past year PLRX has reported a negative cash flow from operations.
  • In the past 5 years PLRX always reported negative net income.
  • In the past 5 years PLRX always reported negative operating cash flow.
PLRX Yearly Net Income VS EBIT VS OCF VS FCFPLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • PLRX has a worse Return On Assets (-69.03%) than 70.68% of its industry peers.
  • The Return On Equity of PLRX (-94.04%) is worse than 62.30% of its industry peers.
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROIC N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
PLRX Yearly ROA, ROE, ROICPLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRX Yearly Profit, Operating, Gross MarginsPLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PLRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PLRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, PLRX has a worse debt to assets ratio.
PLRX Yearly Shares OutstandingPLRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLRX Yearly Total Debt VS Total AssetsPLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -4.57, we must say that PLRX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.57, PLRX is not doing good in the industry: 61.78% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.14 indicates that PLRX is not too dependend on debt financing.
  • The Debt to Equity ratio of PLRX (0.14) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC9.71%
PLRX Yearly LT Debt VS Equity VS FCFPLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • PLRX has a Current Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 12.99, PLRX belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
  • PLRX has a Quick Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 12.99, PLRX belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.99
Quick Ratio 12.99
PLRX Yearly Current Assets VS Current LiabilitesPLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.77% over the past year.
  • PLRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.74%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 5.90% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.08%
EPS Next 2Y12.63%
EPS Next 3Y18.81%
EPS Next 5Y5.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLRX Yearly Revenue VS EstimatesPLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
PLRX Yearly EPS VS EstimatesPLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRX Price Earnings VS Forward Price EarningsPLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRX Per share dataPLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • PLRX's earnings are expected to grow with 18.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.63%
EPS Next 3Y18.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PLIANT THERAPEUTICS INC

NASDAQ:PLRX (2/20/2026, 3:48:02 PM)

1.245

-0.05 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners83.72%
Inst Owner Change2.24%
Ins Owners1.96%
Ins Owner Change-1.66%
Market Cap76.51M
Revenue(TTM)N/A
Net Income(TTM)-206.96M
Analysts51.67
Price Target3.32 (166.67%)
Short Float %6.97%
Short Ratio3.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.31%
Min EPS beat(2)-24.53%
Max EPS beat(2)-0.1%
EPS beat(4)2
Avg EPS beat(4)-0.63%
Min EPS beat(4)-24.53%
Max EPS beat(4)18.2%
EPS beat(8)5
Avg EPS beat(8)2.55%
EPS beat(12)8
Avg EPS beat(12)3.26%
EPS beat(16)10
Avg EPS beat(16)2.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)4.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-2.88
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS0
BVpS3.58
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.99
Quick Ratio 12.99
Altman-Z -4.57
F-Score3
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)109.27%
Cap/Depr(5y)114.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.74%
EPS Next Y28.08%
EPS Next 2Y12.63%
EPS Next 3Y18.81%
EPS Next 5Y5.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.19%
EBIT Next 3Y15.12%
EBIT Next 5YN/A
FCF growth 1Y-60.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.67%
OCF growth 3YN/A
OCF growth 5YN/A

PLIANT THERAPEUTICS INC / PLRX FAQ

What is the ChartMill fundamental rating of PLIANT THERAPEUTICS INC (PLRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to PLRX.


Can you provide the valuation status for PLIANT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PLIANT THERAPEUTICS INC (PLRX). This can be considered as Overvalued.


What is the profitability of PLRX stock?

PLIANT THERAPEUTICS INC (PLRX) has a profitability rating of 0 / 10.


Can you provide the financial health for PLRX stock?

The financial health rating of PLIANT THERAPEUTICS INC (PLRX) is 4 / 10.


Can you provide the expected EPS growth for PLRX stock?

The Earnings per Share (EPS) of PLIANT THERAPEUTICS INC (PLRX) is expected to grow by 28.08% in the next year.